A diagnostics executive at a top pharma company discusses their current explorations of MRD and ctDNA monitoring. They are most familiar with Natera and Guardant as vendors, and in the future, they expect tumor-agnostic testing will be favored for broader use. They also provided feedback on ArcherDx, C2I and Grail. While they see utility of these technologies most in CRC and lung cancers, they imagine that there is potential for use in other indications such as breast, prostate, and ovarian cancers. This stakeholder mentioned these technologies already support registrational cancer trials for both targeted and immuno-oncology therapies. They believe that clinician education will be key hurdle needed to drive adoption.

Campaign Details

MRD Ad Board

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care